to be really bad for the likes of FirstGroup, Arriva and Go-Ahead Group because they are now too weak to fight an encroachment on their turf by the government. It will be interesting to see how this turns out because nationalisation really goes against the Conservative mindset – but then again if the government doesn’t do anything drastic now there may be no railway industry left. Long-time critics of the railways will no doubt see this as a golden opportunity to put things right (or at least on the right footing).
Covid and Brexit could see UK manufacturers bringing it all back home (The Guardian, Sarah Butler) cites a report by Alvarez & Marsal and research group Retail Economics which suggests that UK factories could be making up to £4.8bn-worth of more goods for British retailers (equivalent to the UK’s entire clothing manufacturing output at the moment) as supply chain worries due to covid and Brexit push British businesses to keep things domestic. Consumers are also getting more interested in sustainability, meaning there is more pressure to source product closer to home. * SO WHAT? * This trend of reshoring is pretty interesting and, given that it’s not easy to do, it would suggest that if demand was not out there it would not be happening. I don’t think this is necessarily just a case of businesses having to pivot – it’s a sign that they are taking a longer term view.
In news on other covid-related trends, UK motor insurers on the road to pandemic profit boost (Financial Times, Oliver Ralph) shows that reduced traffic levels and accidents have meant that motor insurers are like to benefit from the coronavirus. Having said that, they will probably lose out in other areas of their business such as travel, meaning that premiums won’t necessarily come down. They will also be wary of giving away too much because they may have to continue to pay out more on whiplash claims due to the delayed introduction of a new system to cut the cost of such claims and they will also have to stop charging existing customers higher rates than new ones for the same products.
House prices soar but beware the slide of March (Daily Telegraph, Russell Lynch) highlights increasing concern from the real estate industry that the end of the stamp duty holiday on purchases up to £500,000 in March next year will result in a massive dive in activity. As things stand right now, the end of March is going to bring three things: the end of the stamp duty holiday, the end of the current Help To Buy Scheme to be replaced by a much less generous plan, and the end of the furlough scheme. * SO WHAT? * This is a very painful-sounding triple whammy – and I would imagine that Sunak will have to do something about that confluence of three major schemes – vaccine, or no vaccine.
Meanwhile, in vaccine-related news, FDA authorises Regeneron’s Covid-19 antibody cocktail drug (Wall Street Journal, Joseph Walker) shows that a treatment that president Trump recently hailed as “unbelieveable” and made him feel good “immediately” was authorised this weekend by the FDA for emergency use for those with mild to moderate Covid over the age of 12. AstraZeneca, Oxford Covid-19 vaccine up to 90% effective in late-stage trials (Wall Street Journal, Jenny Strasburg) highlights more good news on vaccine development BUT that the average efficacy rate was about 70% depending on the dosage given. * SO WHAT? * It’s great that a third potential vaccine – in addition to Pfizer/BioNTech’s and Moderna’s candidates – is on the scene. It is also notable in that it is likely to be distributed more widely as both AstraZeneca and Oxford University have committed to selling it at cost during the pandemic.